Georgia Tech Team Claims 100 Percent Accuracy for Metabolomic Ovarian Cancer Test in Initial Trial
August 20, 2010
Georgia Tech Team Claims 100 Percent Accuracy for Metabolomic Ovarian Cancer Test in Initial Trial
Results from the 94-subject study suggest that the test could be useful in screening high-risk patients for ovarian cancer and possibly even as a screening diagnostic for the general population, a Georgia Tech researcher said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- HealthLinx Restarts Sales of OvPlex Ovarian Cancer Test, Launches 1,150-Patient International Trial
June 18, 2010 / ProteoMonitor - Is Healthlinx Eyeing Purchase of Correlogic's Assets as Part of Move into US Cancer Dx Market?
October 14, 2011 / ProteoMonitor - Court Approves Sale of Correlogic’s Assets to Vermillion after Second Bidder Drops Out
December 2, 2011 / ProteoMonitor - Vermillion Buys Correlogic's Assets for $435K; Correlogic Settles with LabCorp, Quest
November 11, 2011 / ProteoMonitor - Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
July 8, 2011 / ProteoMonitor